SBP in patients with cirrhosis and ascites. . Seven states were shown, three of which constituted the between $2934 and $9251 per patient per year. The entry points of separate analyses: patients without a previous groups that benefited most from prophylaxis were pahistory of SBP, patients without a history of SBP but an ascitic tients with an ascitic fluid total protein concentration fluid total protein concentration of°1 g/dL, and patients with of°1 g/dL and those with a previous history of SBP.
previous episodes of SBP. After entry into the model, patients Conclusions: The use of prophylactic antibiotics to dewere distributed among the remaining four states: the first crease the incidence of SBP is a cost-saving strategy episode of SBP (primary SBP), resolution of SBP, recurrent in patients with cirrhosis and ascites.
SBP, and death. A patient with cirrhosis and ascites was considered to be in one of the three entry states or four subsequent states.
S
The transition between states was governed by the probabilpontaneous bacterial peritonitis (SBP) is a frequent and severe complication in cirrhotic patients with ities of sustaining a first episode of SBP, resolving each episode ascites. The hospital mortality rate of patients diagnosed of SBP, experiencing recurrent SBP, and death attributed to with SBP ranges from 30% to 50%. [1] [2] [3] [4] quent seeding of ascitic fluid. 9, 10 Exploiting this route existed. Published studies showed a difference in the efficacy of SBP prevention between the two antibiotic regimens; however, the study populations differed in the proportion of patients with previous SBP or in the protein concentration of the patients' ascitic fluid. For this analysis, the efficacy of the two antibiotic regimens was assumed to be equivalent within the same patient population. For example, the annual probability of recurrent SBP in patients with a history of SBP treated with prophylactic norfloxacin is 20%. 11 No such data for trimethoprim-sulfamethoxazole prophylaxis exists; therefore, the SBP recurrence rate was assumed to be equivalent to the norfloxacin rate. A sensitivity analysis then varied the efficacy rates to account for possible differences between the antibiotics. The proportion of patients in each state was determined, and the direct costs of treatment that arose from drugs and hospitalization were accumulated every 5 days for a duration of 1 year. All analyses were performed from the perspective of trimethoprim-sulfamethoxazole ($1.00 per double-strength tablet) and from the charges covered by HCFA for treatment of SBP. Norfloxacin (400 mg daily) was used in two prospective of SBP remained in the two entry states labeled 1 and 2 of trials, 11, 12 trimethoprim-sulfamethoxazole (160 mg/800 mg 5 the model. The probability of remaining in these states was 1 days per week) was used in a third trial, 13 and ciprofloxacin minus the probability of developing primary SBP. Similarly, (750 mg weekly) was used in a fourth trial, 14 although cipatients with resolved or previous SBP remained in their correprofloxacin therapy was not modeled in the present study. sponding states unless they developed recurrent SBP. The
Costs
Patients treated with prophylactic antibiotics were assumed to probability of maintaining these states was 1 minus the probatake the medication on a continuous basis except for episodes bility of recurrent SBP.
of SBP, whereupon intravenous antibiotics would be instituted Bacterial peritonitis is not the only cause of death in patients and prophylactic antibiotic use would be suspended. with SBP, and other factors associated with chronic liver disDirect costs of SBP were determined using payments alloease may contribute to mortality. The influence of these other cated by HCFA for treatment of SBP during fiscal year 1994 factors on mortality is encompassed by the overall death rate ( Table 2) . Hospital disbursements were determined by diagnoof patients with SBP used in the present study. However, sis-related group (DRG) codes, whereas physician services were death related to age or causes other than chronic liver disease added according to payments made by HCFA by current procewere not considered in the model for two reasons. First, their dure terminology (CPT) code. No indirect costs were included contribution to mortality pales in comparison to the strong in the analyses. DRG category 202 is designated for use with influence of SBP-related death. Second, death rates from causes patients admitted for cirrhosis or alcoholic hepatitis. CPT other than chronic liver disease and SBP are not affected by codes were added to reflect the physician charges associated antibiotic therapy and, therefore, would have no influence on with hospitalization for SBP, including a limited ultrasound the comparison of different management strategies.
examination of the abdomen, initial and follow-up paracenteses The analyses were begun with a hypothetical group of 100 with appropriate microbiology and microscopic examination patients with ascites and cirrhosis. Every 5 days (the recomof fluid, and hospital care for 5 days. It should be noted that mended inpatient treatment duration for confirmed SBP), the charges and costs are not necessarily the same. The HCFA data patients were redistributed among the seven states according used in this analysis relate to payment for services provided to the probabilities shown in Table 1 , which were derived to patients covered by Medicare. Depending on the type of from existing literature. The rates of transition from state to service, the reimbursement rate from HCFA to the health state were assumed to remain constant throughout the year.
provider may be only 50% of the allowable charges. The rates were taken only from studies with a prospective design and in which the outcome of antibiotic prophylaxis had
The results of our analysis pertain to three different patient groups: (1) patients without a history of SBP, (2) patients with been tested in a randomized clinical fashion. The model assessed the influence of norfloxacin and trimethoprim-sulfaan ascitic fluid total protein concentration of°1 g/dL, and (3) patients with a previous history of SBP. These groups varied methoxazole prophylaxis because these two antibiotics comprised the two regimens for which the majority of such data by their incidence rates of primary and recurrent SBP. The / 5e21$$0016 09-09-97 08:53:55 gasa WBS-Gastro Using a hypothetical population of 100 patients, the model shows that, during the span of 1 year without Sensitivity Analysis the use of prophylactic antibiotics, patients with cirrhosis
To test the robustness of the model, we performed a and ascites and no previous history of SBP accumulate a sensitivity analysis. The incidence rates of SBP and the mortalmean cost per patient of $4765 per year ( Figure 2 ). The ity rates of SBP were varied in separate, one-way analyses. The impact on the cost of SBP treatment with varying rates of SBP was evaluated. Rates found in the literature that were both higher and lower than the baseline SBP rate with antibiotic prophylaxis were used and are shown in Table 1 . 10-13 The effect of varying the baseline SBP mortality rate from 20% to 40% [11] [12] [13] [14] was also determined, and the results were expressed as the cost of prophylactic antibiotics per year-life saved. Two threshold analyses were also performed: one to examine the impact of varying the cost of inpatient treatment of SBP and the other to evaluate various rates of primary SBP. To determine the threshold cost of SBP treatment, the point at which costs of treatment strategies both with and without antibiotics were equal was determined. Below this threshold, antibiotic prophylaxis would not provide an economic benefit. In an analysis of patients without a history of SBP, the rate of primary SBP was varied to determine the rate at which the costs of treatment strategies with and without antibiotics were equal. In this manner, the minimum rate at which antibiotic prophylaxis still resulted in lower costs was determined. SBP from 31% to 20% increased the cost per life-year total protein of°1 g/dL has an even greater impact by saved to $16,538, whereas increasing the mortality rate decreasing direct costs by $3980 per patient per year or to 40% decreased the cost per life-year saved to $10,890. by $4692 with trimethoprim-sulfamethoxazole. The
As the mortality associated with SBP increased, the cost most dramatic effect is observed in the population of per life-year saved decreased, and antibiotic prophylaxis patients in whom SBP had occurred previously; the became an even greater cost-saving strategy. model predicts a decrease in the costs per patient per Threshold analysis was performed to examine the effect year of $8545 with norfloxacin and $9251 with trimethoof varying the cost of inpatient treatment of SBP. In the prim-sulfamethoxazole.
group of patients without a prior history of SBP, use of In the group of 100 patients without a history of norfloxacin prophylaxis continued to constitute a cost-SBP, a total of 38 episodes of SBP will occur (Table  saving strategy as long as the inpatient treatment costs 3). Antibiotic prophylaxis will, according to the model, of SBP exceeded a threshold of $3842; if costs of SBP decrease the number of episodes of SBP in this group by treatment decreased to below this value, prophylaxis 25. Patients with low ascitic fluid protein concentrations will have 39 fewer SBP episodes with antibiotic prophylaxis. In patients with a prior history of SBP, the number Antibiotic prophylaxis results in a decrease in mortal-
No. of SBP Group episodes Deaths ity attributable to SBP (Table 3 ). In a population of 100 patients, antibiotic prophylaxis decreases deaths per year changes in the cost of SBP using varying rates of antibi-/ 5e21$$0016 09-09-97 08:53:55 gasa WBS-Gastro failed to provide economic benefit. Likewise, use of triwith the use of prophylactic antibiotics in patients with low ascitic fluid total protein concentrations and in pamethoprim-sulfamethoxazole was cost-saving above a threshold of $1006 for inpatient treatment costs.
tients with a previous history of SBP. The cost benefit is less in patients with high ascitic fluid protein concenThreshold analysis was also performed to determine the lowest primary SBP rate at which antibiotic prophytrations and without previous SBP. Sensitivity analysis yielded a threshold primary SBP rate of 19%, which is laxis would still provide cost benefit. With a primary SBP rate of ¢19%, antibiotic use resulted in reduced 9% less than the rate reported in the literature. Thus, in this group of patients, the recommendations in favor costs; less than this SBP rate, antibiotic prophylaxis failed to constitute a cost-saving strategy.
of or against prophylaxis with norfloxacin depend on the accuracy of the published rate of SBP. With a margin Discussion this small, it is difficult to be assured of the cost-savings of antibiotic prophylaxis in patients without low ascitic We find a decrease in direct costs associated with fluid protein or a history of SBP. the treatment of SBP with the use of prophylactic antibiThere is a decrease in the mortality from SBP with otics. The savings are most prominent in patients who the use of prophylactic antibiotics. This stems from a have an ascitic fluid total protein of°1 g/dL and in decrease in the total number of SBP episodes that occur those who have had a previous episode of SBP, but benefit with prophylaxis, combined with the high mortality rate is also noted in all patients with cirrhosis and ascites. associated with SBP. Previous clinical trials have not Threshold analysis shows that antibiotic prophylaxis reshown significant survival benefit with prophylactic antimains beneficial for a wide range of SBP treatment costs. biotic use. Singh et al. noted a trend towards survival The model also predicts a decrease in the number of benefit with the use of trimethoprim-sulfamethoxazole, deaths attributable to SBP by 8%-23% per year, debut this result did not achieve statistical significance.
13
pending on the type of patient population studied. Survival was not an outcome parameter in the study by Direct costs only were used in this study. Indirect Ginés et al.; the variable of interest was recurrence of costs, such as income lost as the result of disability or SBP, and thus, no conclusion was made concerning the death of patients or complications of antibiotic therapy, survival benefit of prophylactic norfloxacin. 11 Although were not included in the study. The advantages of using mortality associated with an episode of SBP is high, the only direct costs are simplification of the model and less actual cause of death is rarely peritonitis. An episode of influence from data that may not be reliable, such as SBP could reflect the degree of hepatic decompensation estimation of the cost of death or the amount of income present, or the comorbid conditions associated with SBP lost from missed work. The disadvantage of omitting may result in excess mortality. If either of these is the indirect costs is that a major contributing variable may be case, antibiotic prophylaxis would not be expected to not accounted for in the analysis. As with any modeling provide survival benefit. If, however, SBP causes an otherprocedure, trade-offs exist between the amount of detail wise avoidable decompensation of hepatic function or built into the model and its applicability to the general triggers a chain of events that lead to death, antibiotic population.
prophylaxis could improve survival. Further clinical trials Crucial to the relevance of this study is the assumption will be necessary to determine the true influence of prothat antibiotic prophylaxis remains effective in decreasphylactic antibiotics on the survival of patients with ciring the frequency of SBP during the time period of 1 rhosis and ascites. year. The median duration of follow-up was 90 days in
We estimate a decrease in the total direct costs of the study by Singh et al., 13 while mean follow-up in treatment of SBP with the use of prophylactic antibiotics the trial by Ginés et al. was 6.4 months (range, 1-in patients with cirrhosis and ascites. The benefit is minor 19 months). 11 Resistant Pseudomonas or Aeromonas were in patients without a previous history of SBP. Increased isolated from the stool of patients treated with prophylacbenefit is noted in patients with an ascitic fluid total tic norfloxacin in the study by Ginés et al. at 1 and 9 protein concentration of°1 g/dL, and the greatest benemonths into therapy 11 ; however, colonization by resistant fit is observed in patients with a previous episode of SBP. bacteria was not documented in any patient of their study
The savings are preserved for a large range of hospital after a follow-up period of 24 months. 15 Although our costs for treatment of SBP and are seen with the use of model suggests cost-savings for time periods beyond 1 either norfloxacin or trimethoprim-sulfamethoxazole. year of prophylaxis, validation of this assumption would
